S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
S&P 500   4,467.71
DOW   35,123.36
QQQ   367.91
2 Tech Stocks to Buy and One to Avoid in August
His system isolated NVIDIA - Here's His Next Buy. (Ad)
3 Stocks to Buy No Matter Which Way Inflation Moves
3 Stocks to Buy After Heavy Insider Buying
Bizarre Amazon Secret — Not Available on CNN, Fox, or MSNBC (Ad)
2 Alternatives To Tesla (1 Safe, 1 More Risky)
The Rivian Market Is About To Shift Into A Higher Gear 
The single greatest medical breakthrough of all time? (Ad)
7 Best Fintech ETFs to Buy Now
How major US stock indexes fared Wednesday, 8/9/2023
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Price Target & Analyst Ratings

$13.74
+0.80 (+6.18%)
(As of 08/9/2023 ET)
Compare
Today's Range
$13.28
$13.92
50-Day Range
$12.82
$14.91
52-Week Range
$12.73
$22.76
Volume
405,898 shs
Average Volume
644,711 shs
Market Capitalization
$1.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.78

Deciphera Pharmaceuticals Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$21.78
58.50% Upside
High Prediction$30.00
Average Prediction$21.78
Low Prediction$9.00
TypeCurrent
8/10/22 to 8/10/23
1 Month Ago
7/11/22 to 7/11/23
3 Months Ago
5/12/22 to 5/12/23
1 Year Ago
8/10/21 to 8/10/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$21.78$21.78$21.78$14.43
Predicted Upside58.50% Upside32.83% Upside32.83% Upside18.64% Upside
Get Deciphera Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.


DCPH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DCPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Deciphera Pharmaceuticals Stock vs. The Competition

TypeDeciphera PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.65
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside58.50% Upside5,107.94% Upside636.81% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/9/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
3/15/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Outperform$23.00+37.31%
2/8/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$25.00+50.78%
2/7/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$28.00 ➝ $30.00+79.53%
1/25/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$25.00 ➝ $30.00+66.20%
1/6/2023Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
1/4/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight$8.00 ➝ $9.00-43.54%
1/4/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$22.00+38.02%
9/11/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$13.00 ➝ $18.00-0.44%
8/29/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$25.00+68.35%
(Data available from 8/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












DCPH Price Target - Frequently Asked Questions

What is Deciphera Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Deciphera Pharmaceuticals stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 7 buy ratings for DCPH. The average twelve-month price prediction for Deciphera Pharmaceuticals is $21.78 with a high price target of $30.00 and a low price target of $9.00. Learn more on DCPH's analyst rating history.

Do Wall Street analysts like Deciphera Pharmaceuticals more than its competitors?

Analysts like Deciphera Pharmaceuticals more than other Medical companies. The consensus rating score for Deciphera Pharmaceuticals is 2.67 while the average consensus rating score for medical companies is 2.65. Learn more on how DCPH compares to other companies.

Is Deciphera Pharmaceuticals being upgraded by Wall Street analysts?

Over the previous 90 days, Deciphera Pharmaceuticals's stock had 1 upgrade by analysts.

Does Deciphera Pharmaceuticals's stock price have much upside?

According to analysts, Deciphera Pharmaceuticals's stock has a predicted upside of 33.44% based on their 12-month price targets.

What analysts cover Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has been rated by Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DCPH) was last updated on 8/10/2023 by MarketBeat.com Staff

My Account -